LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 9 of 87
Next
>>
>
201 to 225 of 2160 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Mitoxantrone	0.04	uM	LJP6	3	C24	72	hr	1657	2695	5505	0.4895	0.2696
BT-20	MK2206	0.04	uM	LJP6	1	F06	72	hr	1657	5234	5505	0.9507	0.9294
BT-20	MK2206	0.04	uM	LJP6	2	F06	72	hr	1657	5286	5505	0.9601	0.9429
BT-20	MK2206	0.04	uM	LJP6	3	F06	72	hr	1657	5585	5505	1.0144	1.0206
BT-20	Neratinib	0.04	uM	LJP5	1	A18	72	hr	1657	4303	5505	0.7816	0.6875
BT-20	Neratinib	0.04	uM	LJP5	2	A18	72	hr	1657	4338	5505	0.7879	0.6966
BT-20	Neratinib	0.04	uM	LJP5	3	A18	72	hr	1657	4916	5505	0.8929	0.8468
BT-20	Nilotinib	0.04	uM	LJP5	1	N18	72	hr	1657	5605	5505	1.0180	1.0258
BT-20	Nilotinib	0.04	uM	LJP5	2	N18	72	hr	1657	5297	5505	0.9621	0.9458
BT-20	Nilotinib	0.04	uM	LJP5	3	N18	72	hr	1657	5190	5505	0.9427	0.9180
BT-20	Nintedanib	0.04	uM	LJP6	1	H06	72	hr	1657	5599	5505	1.0170	1.0243
BT-20	Nintedanib	0.04	uM	LJP6	2	H06	72	hr	1657	5867	5505	1.0656	1.0939
BT-20	Nintedanib	0.04	uM	LJP6	3	H06	72	hr	1657	5725	5505	1.0398	1.0570
BT-20	NU7441	0.04	uM	LJP5	1	C12	72	hr	1657	5458	5505	0.9913	0.9876
BT-20	NU7441	0.04	uM	LJP5	2	C12	72	hr	1657	5850	5505	1.0625	1.0895
BT-20	NU7441	0.04	uM	LJP5	3	C12	72	hr	1657	5901	5505	1.0718	1.1027
BT-20	Dactolisib	0.04	uM	LJP5	1	M18	72	hr	1657	2770	5505	0.5031	0.2891
BT-20	Dactolisib	0.04	uM	LJP5	2	M18	72	hr	1657	2836	5505	0.5151	0.3062
BT-20	Dactolisib	0.04	uM	LJP5	3	M18	72	hr	1657	2680	5505	0.4868	0.2657
BT-20	NVP-TAE684	0.04	uM	LJP6	1	K18	72	hr	1657	5559	5505	1.0097	1.0139
BT-20	NVP-TAE684	0.04	uM	LJP6	2	K18	72	hr	1657	5311	5505	0.9646	0.9494
BT-20	NVP-TAE684	0.04	uM	LJP6	3	K18	72	hr	1657	5619	5505	1.0206	1.0295
BT-20	Palbociclib	0.04	uM	LJP6	1	E18	72	hr	1657	3779	5505	0.6864	0.5513
BT-20	Palbociclib	0.04	uM	LJP6	2	E18	72	hr	1657	4029	5505	0.7318	0.6162
BT-20	Palbociclib	0.04	uM	LJP6	3	E18	72	hr	1657	4365	5505	0.7928	0.7036

|<
<<
Previous
Page 9 of 87
Next
>>
>
201 to 225 of 2160 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)